[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:solid-neoplasm:mtap-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Solid Neoplasm","MTAP Gene",16,[8,16,23,30,36,42,48,54,60,66,72,78,84,90,96,103],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06630416","Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors",[12],"Phase 2","RECRUITING","2026-08-26T02:15:00.557154Z","2026-07-05T05:32:16.766648Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06130553","A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced\u002FMetastatic Solid Tumors",[20],"Phase 1\u002FPhase 2","2026-08-26T02:15:45.413021Z","2026-07-05T05:32:16.744919Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT07601243","Study of GS-2426 in Participants With Advanced Solid Tumors",[27],"Phase 1","2026-08-26T02:17:15.156099Z","2026-07-05T03:45:20.254014Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT06414460","Study of ISM3412 in Participants With Locally Advanced\u002FMetastatic Solid Tumors",[20],"2026-08-26T02:16:47.762107Z","2026-06-18T12:24:03.105083Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT06589596","An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors",[27],"2026-08-26T02:18:24.494016Z","2026-05-05T02:43:28.661301Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT07128303","Study of GS-5319 in Adults With Solid Tumors",[27],"2026-08-26T02:15:54.846520Z","2026-05-05T02:43:27.244763Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT06914128","A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors",[20],"2026-08-26T02:19:08.862440Z","2026-07-05T05:32:16.701684Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT07382544","Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss",[27],"2026-08-26T02:16:24.970704Z","2026-05-05T02:43:26.931101Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT06810544","Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss",[20],"2026-08-26T02:15:10.362237Z","2026-05-05T02:43:26.714299Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT07277413","A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors",[27],"2026-08-26T02:16:01.910993Z","2026-07-05T05:32:16.679197Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT07492680","A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and\u002For Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)",[12],"2026-08-26T02:17:47.813245Z","2026-06-16T05:54:07.939792Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT07594626","BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion",[20],"2026-08-26T02:17:39.048487Z","2026-05-29T15:36:40.204907Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT05732831","Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors",[20],"2026-08-26T02:18:40.612983Z","2026-05-05T02:43:27.947953Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT05245500","Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion",[27],"2026-08-26T02:18:27.904411Z","2026-05-05T02:43:26.709142Z",{"nct_id":97,"title":98,"phases":99,"status":100,"updated_at":101,"content_modified":102},"NCT06360354","A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)",[27],"ACTIVE_NOT_RECRUITING","2026-08-03T03:26:30.254593Z","2026-05-05T02:43:29.347634Z",{"nct_id":104,"title":105,"phases":106,"status":100,"updated_at":107,"content_modified":108},"NCT06188702","S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP",[20],"2026-08-03T03:02:32.170340Z","2026-05-05T02:43:28.020362Z"]